Creative Diagnostics launches new antigens for infectious livestock diseases
Creative Diagnostics announced the launch of more than 20 antigens for the development of veterinary diagnostics and vaccines against infectious diseases.
New York, United States – July 27, 2022 – Creative Diagnostics, a world leader in providing raw materials, antibodies and reagents for the biotechnology industry, announced the launch of more than 20 antigens for a variety of veterinary viral, bacterial and parasitic diseases, which are designed to advance the development of diagnostics and vaccines for veterinary infectious diseases.
Intensive farming creates the conditions for the emergence and amplification of epidemics. As demonstrated by the COVID-19 pandemic, the social costs of zoonotic diseases can become enormous. Certain pathogens pose a real risk of severe food shortages in many parts of the world. In 2018, the African swine fever virus (ASFV) spread in Asia, affecting more than 10% of the total pig population in several countries, causing serious economic losses to the pig industry. Therefore, the control of livestock pathogens is an important part of efficient food production. Veterinary infectious disease research continues to focus on pathogens that cause infectious disease, epidemiology, diagnostic methods, molecular evolution, immune response, treatment and prevention.
Combined with diagnostics, the delivery of effective vaccine strategies for the control of major livestock pathogens is particularly tested, and a continuum of new and better vaccines capable of delivering longer and longer lasting protective immunity and being effective against many multiple strains or variants are essential. Researchers need to learn more about key issues in pathogen biology, such as predictions of virus virulence and spread in different situations, immunological mechanisms of protection against disease and virus replication, how to generate longer-lasting protective immunity after vaccination, drivers of viral evolution, and ways to improve the stability and protection of vaccines against multiple serotypes.
To accelerate the development of diagnostics and vaccines for veterinary infectious diseases, Creative Diagnostics now offers more than 20 antigens for various viral, bacterial and parasitic veterinary diseases, such as the recombinant protein CSFV E2 [His] (DAGC032), a recombinant protein from CHO cells for classical swine fever virus (CSFV) polyprotein research. CSFV is an icosahedral symmetrically enveloped virus with virions between 40 and 60 nm in diameter. The enveloped glycoprotein E2 is the main neutralizing antigen in CSFV infection. E2-based vaccines protect pigs against CSFV and induce neutralizing antibodies. The E2 structural protein of CSFV has been expressed in different systems. Additionally, CSFV-specific antibody detection assays and animal immunization experiments have been developed using the recombinant E2 protein.
Recombinant bovine viral diarrhea virus E2 protein (DAG-WT723) is another recently published bovine viral diarrhea virus (BVDV) E2 protein, an E. coli recombinant. BVD is an economically important bovine disease found in most countries of the world. Meanwhile, the causative agent, bovine viral diarrhea virus is a member of the genus Pestivirus in the family Flaviviridae.
If you would like to learn more about infectious disease antigens of livestock or have questions regarding research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com.
About creative diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract R&D and manufacturing services of biologics to diagnostics manufacturers as well as manufacturing of GMP-compliant biologics for the biopharmaceutical market. It aims to provide a trusted source for all researcher assay development and manufacturing needs.
Company Name: Creative diagnosis
Contact person: Thomas Schmitt
E-mail: Send an email
Country: United States